Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 6/20 | 0.46 |
| ▸ | CDC25B | P30305 | 6/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.40 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.40 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.40 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.40 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.40 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.40 |
| ▸ | BCHE | P06276 | 4/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16027344 | 1.00 | PTPN1 (0.46) | PTPN1CDC25BPDPK1MTORSSTR1 | |
| SCHEMBL20056306 | 1.00 | PTPN1 (0.46) | PTPN1CDC25BPDPK1MTORSSTR1 | |
| SCHEMBL4283122 | 1.00 | PTPN1 (0.46) | PTPN1CDC25BPDPK1MTORSSTR1 | |
| SCHEMBL16027439 | 1.00 | PTPN1 (0.46) | PTPN1CDC25BPDPK1MTORSSTR1 | |
| SCHEMBL16027346 | 1.00 | PTPN1 (0.46) | PTPN1CDC25BPDPK1MTORSSTR1 | |
| SCHEMBL16027437 | 1.00 | PTPN1 (0.46) | PTPN1CDC25BPDPK1MTORSSTR1 | |
| SCHEMBL16076882 | 0.90 | PTPN1 (0.43) | PTPN1CDC25BPDPK1MTORSSTR1 | |
| SCHEMBL8949507 | 0.90 | PTPN1 (0.42) | PTPN1CDC25BPDPK1MTORSSTR1 | |
| SCHEMBL8949600 | 0.90 | PTPN1 (0.42) | PTPN1CDC25BPDPK1MTORSSTR1 | |
| SCHEMBL16027499 | 0.89 | PTPN1 (0.47) | PTPN1CDC25BPDPK1MTORSSTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137499-A1 | BENZYLPHENYL GLUCOPYRANOSIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-2048150-A1 | BENZYL PHENYL GLUCOPYRANOSIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2009-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137499-A1 | BENZYLPHENYL GLUCOPYRANOSIDE DERIVATIVE | SLC5A1, SLC5A2, SLC2A1 | PTPN1 1591/4885CDC25B 4229/4885PDPK1 3526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.